Preclinical testing of N-[11C]-methyl-piperidin-4-yl 2-cyclohexyl-2- hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET

Synapse

Volumn 35, Issue 1, 2000, Pages 62-67

  Visser, Thomas Jakob ^a   Van Waarde, Aren ^a   Doze, Petra ^a   Wegman, Theodora ^a   Vaalburg, Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atropine; Brain; M2 subtype; Positron emission tomography; Receptor imaging

Indexed keywords

MUSCARINIC RECEPTOR; N METHYLPIPERIDIN 4 YL 2 CYCLOHEXYL 2 HYDROXY 2 PHENYLACETATE CARBON 11; RADIOLIGAND; UNCLASSIFIED DRUG; VC 004;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SCREENING; IMAGE ANALYSIS; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

ANIMALS; BRAIN; MALE; MUSCARINIC ANTAGONISTS; PHENYLACETATES; QUINUCLIDINYL BENZILATE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033990420     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(200001)35:1<62::AID-SYN8>3.0.CO;2-1     Document Type: Article

References (35)

1. 125I]-4IQNB binding to the muscarinic acetylcholine receptor in relationship to the regional subtype composition. Receptor 5:207-218.
2. Boulay SF, Sood VK, Rayeq MR, Cohen VI, Zeeberg BR, Reba RC. 1996. Autoradiographic evidence that 3-quinuclidiny1-4-fluorobenzilate (FQNB) displays in vivo selectivity for the m2 subtype. Neuroimage 3:35-39.
3. 11C]levetimide. Appl Radiat Isotop 39:291-295.
4. 11C-methyl]benztropine. Synapse 5:213-223.
5. Eglen RM, Watson N. 1996. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol 78:59-69.
6. Ehlert FJ, Tran LP. 1990. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain. J Pharmacol Exp Ther 255:1148-1157.
7. 11C-scopolamine and positron emission tomography. J Cereb Blood Flow Metab 12:147-154.
8. Frost JJ, Dannals RF, Duelfer T, Burns HD, Ravert HT, Långström B, Balasubramanian V, Wagner HN. 1984. In vivo studies of opiate receptors. Ann Neurol 15:S85-S92.
9. 125I]IQNB. Brain Res 687:71-78.
10. Golding JF, Stott JR. 1997. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 43:633-637.
11. Goyal RK. 1989. Muscarinic receptor subtypes. Physiology and clinical implications. N Engl J Med 321:1022-1029.
12. 18F]fluorodexetimide. Synthesis and biodistribution. Nucl Med Biol 18:247-252.
13. Imeri L, Bianchi S, Angeli P, Mancia M. 1994. Selective blockade of different brain stem muscarinic receptor subtypes: effects on the sleep-wake cycle. Brain Res 636:68-72.
14. Inch TD, Green DM, Thompson PB. 1973. The central and peripheral activities of anti-acetylcholine drugs. Some concepts of practical relevance. J Pharm Pharmacol 25:359-370.
15. 18F]-fluoromethyl QNB. Bioorg Med Chem 5:1555-1567.
16. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. 1992. Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 239:103-104.
17. Lee J, Paik CH, Kiesewetter DO, Park SG, Eckelman WC. 1995. Evaluation of stereoisomers of 4-fluoroalkyl analogues of 3-quinuclidinyl benzilate in in vivo competition studies for the M1, M2, and M3 muscarinic receptor subtypes in brain. Nucl Med Biol 22:773-781.
18. Levey AI. 1996. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 93:13541-13546.
19. 76Br]bromolevetimide. Nucl Med Biol 23:235-243.
20. Mash DC, Flynn DD, Potter LT. 1985. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117.
21. McRee RC, Boulay SF, Sood VK, Cohen EI, Cohen VI, Gitler MS, Zeeberg BR, Gibson RE, Reba RC. 1995. Autoradiographic evidence that QNB displays in vivo selectivity for the m2 subtype. Neuroimage 2:55-62.
22. Mulholland GK, Otto CA, Jewett DM, Kilbourn MR, Koeppe RA, Sherman PS, Petry NA, Carey JE, Atkinson ER, Archer S. 1992. Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2-alpha-tropanyl benzilate: a central muscarinic receptor imaging agent. J Nucl Med 33:423-430.
23. 11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl Med Biol 22:13-17.
24. Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, Araujo DM. 1989. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol Sci (Suppl):80-84.
25. Reever CM, Ferrari-Dileo G, Flynn DD. 1997. The M5 (m5) receptor subtype: fact or fiction? Life Sci 60:1105-1112.
26. Reinikainen KJ, Riekkinen PJ, Halonen T, Laakso M. 1987. Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease. Life Sci 41:453-461.
27. Rinne JO, Lonnberg P, Marjamaki P, Rinne UK. 1989. Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease. Brain Res 483:402-406.
28. 3H]methylscopolamine labeling of non-M1, non-M2 muscarinic receptor binding sites in rat brain. J Pharmacol Exp Ther 256:1173-1181.
29. 76Br] BrQNP. Eur J Nucl Med 24:475-482.
30. Trovero F, Brochet D, Breton P, Tambute A, Begos A, Bizot JC. 1998. Pharmacological profile of CEB-1957 and atropine toward brain muscarinic receptors and comparative study of their efficacy against sarin poisoning. Toxicol Appl Pharmacol 150:321-327.
31. 11C]quinuclidinyl benzilate and positron emission tomography in baboons. Eur J Pharmacol 213:275-284.
32. 11C]-labeled antagonists for positron emission tomography imaging of muscarinic receptors in the airways. J Med Chem 40:117-124.
33. 11C]formoterol and positron emission tomography. Eur J Pharmacol 361:35-41.
34. Visser TJ, Van Waarde A, Van der Mark. TW, Kraan J, Ensing K, Vaalburg W. 1999. Detection of muscarinic receptors in the human lungs using PET. J Nucl Med 40:1270-1276.
35. Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, Weisstein JS, Spagnola BV, Wolfe BB. 1993. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149-157.